Evidence map›Paper›PMID 41652494›Full record

ArticleJournal of nanobiotechnology2026

Microfluidics engineered autologous nanovaccine for activating and visualizing antitumor activity.

Xiaoting Jiang, Jiacheng Song, Yunfei Mu, Guangyue Zu, Ruiheng Wang, Xisheng Liu, Xianguang Ding, Ting Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xiaoting Jiang *Department of Radiology, the First Affiliated Hospital with Nanjing Medical University, Nanjing, 210029, China.
Jiacheng Song *Department of Radiology, the First Affiliated Hospital with Nanjing Medical University, Nanjing, 210029, China.
Yunfei MuState Key Laboratory of Organic Electronics and Information Displays and Jiangsu Key Laboratory for Biosensors, Institute of Advanced Materials (IAM), Nanjing University of Posts and Telecommunications, Nanjing, 210023, China.
Guangyue ZuCAS Key Laboratory of Nano-Bio Interface, Division of Nanobiomedicine, Suzhou Institute of Nano-Tech and Nano-Bionics, Chinese Academy of Sciences, Suzhou, 215123, China.
Ruiheng WangDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Los Angeles, CA, 91010, USA.
Xisheng LiuDepartment of Radiology, the First Affiliated Hospital with Nanjing Medical University, Nanjing, 210029, China. liuxisheng2013@163.com.
Xianguang DingState Key Laboratory of Organic Electronics and Information Displays and Jiangsu Key Laboratory for Biosensors, Institute of Advanced Materials (IAM), Nanjing University of Posts and Telecommunications, Nanjing, 210023, China. iamxgding@njupt.edu.cn.
Ting ChenDepartment of Radiology, the First Affiliated Hospital with Nanjing Medical University, Nanjing, 210029, China. chentingwzc@163.com.

Funding

Natural science foundation of China 82071919
6 · The paper itself

Abstract

Tumor-derived extracellular vesicles (TEVs) are promising autologous cancer vaccines due to their intrinsic tumor-associated antigens. However, their translation is hindered by immune evasion and the lack of non-invasive tools to monitor vaccination efficacy in vivo. Here, we report a self-reporting nanovaccine engineered by coating TEVs under microfluidics with pH-sensitive manganese dioxide (mTEV). This surface biomineralization on TEVs chemically block inhibitory ligands such as CD47, promoting dendritic cell (DC) uptake and degrades under lysosomal conditions to expose tumor antigens and release Mn

Indexed as

Cancer VaccinesMicrofluidicsNanovaccinesAnimalsAntigens, NeoplasmCell Line, TumorDendritic CellsExtracellular VesiclesFemaleHumansMagnetic Resonance ImagingManganese CompoundsMiceOvarian NeoplasmsOxidesAntigens, NeoplasmCancer VaccinesManganese Compoundsmanganese dioxideNanovaccinesOxidesAutologous tumor vaccineDendritic cellExtracellular vesicleMagnetic resonance imaging

Identifiers

PMID41652494
PMCPMC12973760

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.